

CORRECTION

Open Access



# Correction: Emotion regulation-enhanced group treatment for gambling disorder: a non-randomized pilot trial

Viktor Månsson<sup>1\*</sup>, Olof Molander<sup>1</sup>, Per Carlbring<sup>2</sup>, Ingvar Rosendahl<sup>1</sup> and Anne H. Berman<sup>1,3</sup>

**Correction: BMC Psychiatry 22: 16 (2022)**  
<https://doi.org/10.1186/s12888-021-03630-3>

Following publication of the original article [1], the authors identified an error in Table 3. The correct table is given below.

The original article [1] has been corrected.

Published online: 23 August 2023

## Reference

1. Månsson, et al. Emotion regulation-enhanced group treatment for gambling disorder: a nonrandomized pilot trial. *BMC Psychiatry*. 2022;22:16. <https://doi.org/10.1186/s12888-021-03630-3>.

---

The original article can be found online at <https://doi.org/10.1186/s12888-021-03630-3>.

\*Correspondence:

Viktor Månsson  
[viktor.mansson@ki.se](mailto:viktor.mansson@ki.se)

<sup>1</sup> Center for Psychiatry Research, Department of Clinical Neuroscience, Karolinska Institutet & Stockholm Health Care Services, Region Stockholm, Norra Stationsgatan 69, 7Tr, 113 64 Stockholm, Sweden

<sup>2</sup> Department of Psychology, Stockholm University, Stockholm, Sweden

<sup>3</sup> Department of Psychology, Uppsala University, Uppsala, Sweden



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

**Table 3** Means and standard deviations of observed primary and secondary outcome measures

| Outcome       | Pre-treatment | Post-treatment | 3-month follow-up | 6-month follow-up | 12-month follow-up | Hedges' <i>g</i> Pre- to post-treatment [95% CI] | Hedges' <i>g</i> Pre- to 12-month follow-up [95% CI] |
|---------------|---------------|----------------|-------------------|-------------------|--------------------|--|--|
| G-SAS         | 25.8 (10.68)  | 16.7 (9.59)    | 16.1 (8.04)       | 13.6 (8.70)       | 13.7 (10.19)       | 0.73 [0.34, 1.14]                                | 1.03 [0.59, 1.49]                                    |
| GUS           | 13.4 (10.93)  | 5.5 (7.33)     | 3.8 (5.55)        | 2.2 (5.78)        | 6.6 (8.39)         | 0.53 [0.16, 0.91]                                | 0.44 [0.07, 0.81]                                    |
| DERS-16       | 41.20 (14.58) | 35.1 (9.51)    | 31.6 (9.92)       | 30.2 (9.02)       | 36.4 (17.18)       | 0.05 [-0.69, 0.78]                               | 0.10 [-0.45, 0.65]                                   |
| GAD-7         | 16.3 (5.54)   | 5.7 (3.54)     | 6.0 (4.18)        | 5.2 (3.75)        | 5.8 (7.21)         | 1.69 [1.13, 2.29]                                | 1.73 [1.16, 2.34]                                    |
| PHQ-9         | 12.7 (5.53)   | 6.4 (4.73)     | 6.4 (4.83)        | 6.4 (4.91)        | 8.3 (6.93)         | 1.33 [0.84, 1.85]                                | 0.59 [0.21, 0.98]                                    |
| AAQ-II        | 28.4 (10.64)  | 19.3 (9.71)    | 19.7 (10.91)      | 19.0 (9.76)       | 18.7 (8.91)        | 0.97 [0.54, 1.42]                                | 1.06 [0.62, 1.53]                                    |
| CEQ-intensity | 41.8 (18.74)  | 25.4 (19.08)   | 24.0 (19.10)      | 21.9 (20.67)      | 34.1 (21.69)       | 0.54 [0.17, 0.92]                                | 0.27 [-0.08, 0.63]                                   |
| CEQ-frequency | 28.7 (17.19)  | 17.5 (16.79)   | 14.6 (15.39)      | 11.9 (17.06)      | 16.3 (21.12)       | 0.53 [0.16, 0.92]                                | 1.34 [0.85, 1.87]                                    |
| ASRS          | 29.7 (14.63)  |                |                   | 20.0 (9.81)       | 22.2 (15.13)       | 0.42 [0.06, 0.79]                                | 0.23 [-0.12, 0.59]                                   |
| AUDIT         | 8.4 (4.15)    | 6.2 (3.46)     | 8.3 (2.89)        | 8.8 (4.6)         | 6.3 (5.10)         | 0.67 [0.28, 1.07]                                | 0.69 [0.30, 1.09]                                    |

Note. G-SAS Gambling Symptoms Assessment Scale, GUS Gambling Urge Scale, DERS Difficulties in emotion regulation Scale, GAD-7 Generalized Anxiety Disorder Scale, PHQ-9 Patient Health Questionnaire, AAQ II Acceptance and action questionnaire, CEQ Craving Experience Questionnaire, ASRS Adult ADHD Self Report Scale (reported Hedge's *g* from pre-treatment to 6 months follow up), AUDIT Alcohol Use Disorder Identification Test